Lexology June 4, 2024
Highlights
- A recent federal court decision, FTC v. U.S. Anesthesia Partners, could prove to be a turning point in the ongoing wave of federal and state scrutiny of private equity investment in healthcare.
- Though the decision was a win for private equity sponsors, the Federal Trade Commission (FTC) remains committed to challenging sponsor-backed healthcare companies to defend their business tactics and goals within an antitrust framework.
- This Holland & Knight alert reviews the anticipated avenues for future challenges and identifies ways private equity sponsors can rise to those challenges through a new level of antitrust sophistication and preparedness.
Private equity sponsors can exhale: A federal court recently stopped the Federal Trade Commission’s (FTC) antitrust action that targeted private...
Today's Sponsors
Today's Sponsor